Thetis Pharmaceuticals LLC
Southport, US · Founded 2011 · Connecticut LLC · 1 known investors
Thetis is a clinical-stage pharmaceutical company developing oral TP-317, a first-in-class drug for treating inflammatory bowel disease and solid tumors by activating BLT1 to restore tissue and immune homeostasis.
Founders & leadership
GF
Gary F MathiasManager & Chief Executive Officer
DW
Dennis WillsonManager
DM
David M WurzerManager
FC
Frank C SciavolinoManager
AM
Alan MendelsonManager
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$1.1MraisedJul 2022 · 9 investors · PharmaceuticalsRule 506(b)
▶$1.1MraisedJul 2022 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gary MathiasExecutive Officer, Director
- Frank C. SciavolinoDirector
- Walter OgierDirector
- Cynthia GreenDirector
- Dennis F. WillsonDirector
- Offering amount
- $2M
- Amount sold
- $1.1M
- Minimum investment
- $10K
- First sale
- Jun 2022
- Incorporated
- Limited Liability Company, Connecticut
- Federal exemptions
- 06b
▶$795.8KraisedAug 2018 · 8 investors · PharmaceuticalsRule 506(b)
▶$795.8KraisedAug 2018 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David M WurzerDirector
- Frank C SciavolinoExecutive Officer, Director
- Dennis F WillsonDirector
- Gary MathiasExecutive Officer, Director
- Walter OgierDirector
- Offering amount
- $2.1M
- Amount sold
- $795.8K
- First sale
- Aug 2018
- Incorporated
- Limited Liability Company, Connecticut
- Federal exemptions
- 06b
▶$4.1MraisedJan 2017 · 52 investors · PharmaceuticalsRule 506(b)
▶$4.1MraisedJan 2017 · 52 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dennis F WillsonDirector
- David M WurzerDirector
- Gary F MathiasExecutive Officer, Director
- Frank C SciavolinoExecutive Officer, Director
- Walter OgierDirector
- Offering amount
- $8M
- Amount sold
- $4.1M
- Sales commissions
- $200K
- Placement agents
- Fairport Capital, Inc.
- First sale
- Jun 2016
- Incorporated
- Limited Liability Company, Connecticut
- Federal exemptions
- 06b
▶$1.4MraisedFeb 2016 · 16 investors · PharmaceuticalsRule 506(b)
▶$1.4MraisedFeb 2016 · 16 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gary F MathiasExecutive Officer, Director
- Dennis WillsonDirector
- David M WurzerDirector
- Frank C SciavolinoDirector
- Alan MendelsonDirector
- Offering amount
- $4M
- Amount sold
- $1.4M
- First sale
- Jan 2016
- Incorporated
- Limited Liability Company, Connecticut, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Thetis Pharmaceuticals Presents New Preclinical and Clinical Data forTP-317 at DDW 2025businesswire.com · 2025
- Thetis Pharmaceuticals Secures an Additional $8.975 Million in Program-Related Investment Funds from the Helmsley Charitable Trust to Advance TP-317, an Oral BLT1 Agonist, into a Phase 1b Trial in Ulcerative Colitis Patientsbusinesswire.com · 2025
- Thetis Pharmaceuticals Announces Appointment of Fabio Cataldi, M.D., to Board of Managers and Scientific Advisory Boardbusinesswire.com · 2024
- Thetis Pharmaceuticals Progressing to Clinic with a Phase 1a Trial of TP-317, an Oral Agonist of BLT1, in Healthy Subjects — Thetis Pharmaceuticalsthetispharma.com · 2024
- Thetis Pharmaceuticals Receives $1.9 Million Fast-Track NIH Grant to Advance Novel Inflammatory Bowel Disease Drug Pipeline Toward Clinical Investigationglobenewswire.com · 2018
- Thetis Pharmaceuticals - Carter Morse & Goodrichcartermorse.com · 2015